Relapsing Remitting Multiple Sclerosis (RRMS) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Relapsing Remitting Multiple Sclerosis (RRMS) – Drugs In Development, 2024 report and make more profitable business decisions.
Relapsing-remitting multiple sclerosis (RRMS) is the most common form of multiple sclerosis (MS), a chronic autoimmune condition that affects the central nervous system. In RRMS, individuals experience intermittent episodes of new or worsening symptoms (relapses or exacerbations) lasting days to weeks, followed by periods of partial or complete recovery (remission) with stable or improved function. Symptoms of RRMS can vary widely and may include fatigue, numbness or tingling, muscle weakness, vision problems, balance and coordination difficulties, cognitive changes, and problems with bladder or bowel function. The severity and specific symptoms can differ among individuals and can also vary over time. During the early stages of RRMS, most individuals experience relapses followed by remissions. Over time, some people may transition to a secondary progressive form of MS, where disability accumulates steadily, with or without relapses. The exact cause of RRMS is not fully understood, but it is believed to involve a complex interaction between genetic, environmental, and immunological factors. In MS, the immune system mistakenly attacks the protective myelin sheath surrounding nerve fibers in the brain and spinal cord, leading to nerve damage and disruption of nerve signals.
The Relapsing Remitting Multiple Sclerosis (RRMS) drugs in development market research report provide comprehensive information on the therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Relapsing Remitting Multiple Sclerosis (RRMS) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 54 molecules, with 53 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Relapsing Remitting Multiple Sclerosis (RRMS) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Relapsing Remitting Multiple Sclerosis (RRMS) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Relapsing Remitting Multiple Sclerosis (RRMS) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAnokion SA
Antisense Therapeutics Ltd
Apimeds Inc
Avidea Technologies Inc
Avotres Inc
Biocon Ltd
Biogen Inc
Cellerys AG
Cellix Bio Pvt Ltd
Celltrion Inc
Centrymed Pharmaceutical Inc
CGeneTech (Suzhou China) Co Ltd
Cinnagen Co
Clene Inc
Denali Therapeutics Inc
EA Pharma Co Ltd
Ever Supreme Bio Technology Co Ltd
F. Hoffmann-La Roche Ltd
Farmacija d.o.o. Tuzla
FibroBiologics Inc
GeNeuro SA
Guangzhou Lupeng Pharmaceutical Co Ltd
Hope Biosciences LLC
Iltoo Pharma
ImCyse SA
Immunic Inc
Imstem Biotechnology Inc
InnoBioscience LLC
Inventage Lab Inc
Johnson & Johnson
Mapi Pharma Ltd
Medsenic SAS
Merck KGaA
Millennium Pharmaceuticals Inc
Mitsubishi Tanabe Pharma Corp
NervGen Pharma Corp
Neurology Center Krzysztof Selmaj
Novartis AG
Oryzon Genomics SA
Polpharma Biologics SA
PolTREG SA
RemeGen Co Ltd
Revalesio Corp
Sanofi
Statera Biopharma Inc
Transparency Life Sciences LLC
UCB SA
Vitalis LLC
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Relapsing Remitting Multiple Sclerosis (RRMS) reports